

Pain among US adults before, during, and after the COVID-19 pandemic.

Anna Zajacova, University of Western Ontario

Hanna Grol-Prokopczyk, University at Buffalo, SUNY

ABSTRACT

Importance: Chronic pain is a major public-health problem in the US. The COVID-19 pandemic led to widespread disruptions in the US. It remains unclear, however, how medical and societal changes during this period affected national chronic pain prevalence, a key dimension of population health.

Objective: To determine prevalence of chronic pain (CP) and high-impact chronic pain (HICP) before, during, and after COVID-19 pandemic and explore reasons driving the trends

Methods: We use data from the 2019, 2021, and 2023 National Health Interview Survey (NHIS), a multi-wave cross-sectional survey. Nationally representative sample of non-institutionalized civilian US population age 18 and older (n=88,469). Year of interview is the exposure. All regression models control for age and sex; some models include additional 19 covariates (demographics, socioeconomic status, health behaviors, health conditions, mental health, and health insurance type); analyses also explore the role of COVID and long COVID. Primary outcomes were the prevalence of CP and HICP measured via widely-used validated measures. CP was based on the question “In the past 3 months, how often did you have pain? Would you say never, some days, most days, or every day?”; CP is defined as pain on most days or every day. HICP was defined as chronic pain that limited life or work activities on most days or every day (versus never or some days).

Results: Chronic pain prevalence was 20.6% (19.9-21.2%) in 2019, 20.9% (20.3-21.6%) in 2021, and 24.3% (23.7-25.0%) in 2023. HICP also increased from 7.5% (7.1-7.8%) in 2019, to 8.5% (8.1-8.9%) in 2023, after a decline to 6.9% (6.6-7.3%) in 2021. The 2023 increases occurred in all examined body sites except for dental pain. COVID and long COVID had a modest role in the population-wide pain increases, the causes of which remain unclear.

Conclusions and Relevance: Pain among US adults was high before the pandemic but surged dramatically since. In 2023, an unprecedented 60 million Americans had chronic pain and 21 million had high-impact chronic pain.

KEYWORDS

Chronic pain; High-impact chronic pain; US adults; Trends; Epidemiology; COVID-19

INTRODUCTION

Chronic pain affects tens of millions of U.S. adults, constituting a public health crisis with profound economic, social, and health consequences. The economic cost of pain---\$560-\$635 billion annually in 2010 dollars---exceeds the cost of heart disease, cancer, or diabetes.¹ Pain affects physical, mental, and cognitive health²⁻⁴ health. It also profoundly impacts all other life domains such as employment⁵ family relationships⁶ sexual function,⁷ and sleep⁸. Correspondingly, monitoring pain trends is one of Healthy People 2030 goals.⁹

Chronic pain across all segments of the US adult population increased in the first two decades of the 21st century¹⁰⁻¹³ but these increases appeared to slow or even reverse by 2020 or 2021.^{14,15} At the beginning of the pandemic, pain researchers warned of potential widespread pain consequences of COVID.¹⁶ Pain could increase as a direct consequence of the viral infection,^{17,18} as well as due to stress, anxiety, depression, loneliness, inactivity, disrupted health care, or social factors like economic hardships during the pandemic.^{16,19,20}

By now, extensive literature has also empirically documented the increased pain linked to COVID infection, especially long COVID.^{18,21-24} Relatively little is known about how all the other social and economic disruptions of the pandemic may have influenced pain prevalence in the US population, however. At this point, only one study compared pain prevalence among US adults in 2021 compared with 2019, finding no increase during the pandemic, and actually a slight decrease for high-impact chronic pain.¹⁴

Our study provides the first findings on pain trends in a nationally representative sample of US adults during and especially after the COVID pandemic. We use National Health Interview Survey data and examine multiple dimensions of pain in the full population and across key demographic subgroups. In addition to chronic pain, we also examine high-impact chronic pain,²⁵ as well as six location-specific pain types. Finally, we explore potential drivers of the observed changes in pain.

METHODS

Data

We analyzed data from the 2019, 2021, and 2023 National Health Interview Survey (NHIS) harmonized by IPUMS.²⁶ The NHIS, approved by the National Center for Health Statistics Research Ethics Review Board, is an ongoing cross-sectional household-based interview survey. It is the “best single source for pain surveillance” among US adults.²⁷

The choice of the three waves---2019, 2021, and 2023---is driven by the NHIS design (sampling and variable collection choices). In 2019, the NHIS underwent a major redesign, which made it potentially problematic to merge older data.²⁸ The years 2020 and 2022 lack key pain variables.

Variables

Two widely-used measures of pain were captured in 2019, 2021, and 2023 (but not in interim waves). Chronic pain (CP) was defined as pain on most days or every day over the past 3 months versus never or some days. High-impact chronic pain (HICP) is CP that also limits activities on most days or every day (versus no CP or CP that never or only on some days limits activities).

In addition to these two global pain measures, we also analyze all available site-specific pain questions. Respondents were asked how much pain they experienced during the past 3 months in the following five sites: back; arm, shoulder, or hand; hip, knee, or feet; headache or migraine; abdominal, pelvic, or genital; and jaw or tooth pain. We classified as having each site-specific pain those who said they had “a lot of” pain at a given site (versus none, a little, or ‘somewhere between a little and a lot.’).

The main predictor is the year of interview.

Covariates include age and sex in all models. In addition, 19 covariates, shown in Supplemental Table S1, measure demographics, socioeconomic status, health-related information.

The final covariate is COVID. The variable is not available for 2019 for obvious reasons; 2021 data only asked about having been “diagnosed with” COVID. 2023 wave asked a detailed battery that allows us to categorize respondents into a 5-level variable based on whether they had COVID, long COVID but in the past, current long COVID, or currently have highly-limiting long COVID (HILC).

Approach

We estimated the weighted crude prevalence of CP and HICP. A similar perspective is obtained from age- and sex-adjusted modified (robust) Poisson models of CP and HICP with adjustments for the NHIS complex sampling design. We then estimated modified (robust) Poisson models of CP and HICP as a function of year, net of different covariate groups. Because the models cannot include COVID information as a covariate (the information is multicollinear with year as there was no COVID in 2019), we tackle its impact by estimating the regression models only on the subsample that claimed no COVID or no long COVID, respectively. As a supplemental analysis, we also estimated models exploring the link between COVID and pain using 2023 data only. Finally, we show results for site-specific pain levels in 2019, 2021, and 2023.

RESULTS

NHIS 2019, 2021, and 2023 included 90,769 respondents age 18 and older; 88,469 (97.5%) answered the lead (CP) pain question.

As Table 1 shows, the weighted crude prevalence of CP was 20.6% (95%CI 19.9-21.2%) in 2019 and 20.9% (95%CI 20.3-21.6%) in 2021 but increased to 24.3% (95%CI 23.7-25.0%) in 2023. Weighted crude prevalence of HICP was 7.5% (95%CI 7.1-7.9%) in 2019, declining to 6.9% (95%CI 6.6-7.3%) in 2021, but increasing to 8.5% (95%CI 8.1-8.9%) in 2023.

The Table also shows that the 2023 increase was common across body sites: back/neck pain, shoulder/arm pain, hip/knee/leg pain, headache/migraine, and abdominal/pelvic pain all changed significantly, increasing in 2023. Only dental/tooth/jaw pain remained stable over time.

Figure 1 visualizes the patterns in the full sample for CP (Plot A) and HICP (Plot B). The Figure also shows that similar patterns are evident by sex, age, and educational attainment: for all population groups, CP and HICP stayed relatively stable or even decreased in 2021 but increased sharply in 2023.

What is behind this post-pandemic pain surge? Supplemental Tables provide some answers. First, Supplemental Table S1 shows the distribution of population characteristics that are known predictors of pain. Demographics did not change significantly (age, sex, region, race/ethnicity, foreign-born) and neither did the prevalence of physical chronic conditions. However, socioeconomic, mental health, health behaviors, and health insurance distributions changed between 2019 and 2023. For instance, food insecurity affected 8.3% of US adults in 2019, dropping to 5.6% in 2021, but surging to 8.6% in 2023.

Supplemental Table S2 thus controls for all these characteristics in regression models of CP and HICP. The results show that the increase cannot be attributed to the covariates: the relative 2023 vs 2019 increase in CP is 18% in age and sex-adjusted models but 22% in fully adjusted models; for CP the prevalence ratios are 13% and 19%, respectively. Supplemental Table S3 further shows that comparable findings are evident for site-specific pain.

Could the increase be due to COVID infections? As Supplemental Table S4 estimated only for 2023 data shows, pain is particularly high among adults with long COVID.

We cannot include COVID information in the full regression models because the information is collinear with 2019 (when nobody had COVID). But we can exclude adults with COVID or those with long COVID from our models (Models 3 and 4 in Supplemental Table S2). The relative CP and HICP increase in 2023 are smaller in absolute size, but they remain statistically significant and large: Excluding all adults with long COVID, CP was still 19% higher in 2023 relative to 2019, and HICP was 16% higher.

COMMENTARY

Chronic pain and high-income chronic pain surged dramatically after the COVID pandemic. The widely-cited 20% prevalence of CP in the adult US population^{14,29,30} appears obsolete; the most recent prevalence estimate from 2023 is 24.3%. This increase represents more than 10 million additional individuals now experiencing chronic pain, bringing the total to over 60 million adults affected. Similarly, high-impact chronic pain, which significantly limits daily activities, affected 8.5% of adults in 2023, up from 7.5% in 2019, translating to over 21 million Americans experiencing debilitating pain.

The observed rise in both CP and HICP in 2023 is concerning, particularly given the stability of chronic pain and decline in HICP in 2021, when prevalence dipped to 6.9%. The 2023 surge is not restricted to specific demographics or body sites—it is widespread across the population subgroups and affects all examined pain sites except jaw/dental pain. Further, the increase persisted even after accounting for potential drivers such as COVID-19 infections, socioeconomic factors, and other potentially important covariates such as mental health or health behaviors. This suggests that a broader, more complex set of factors may be at play.

While COVID-19 and long COVID have been linked to increased prevalence of chronic pain, including in our analyses, these alone do not fully explain the population-wide rise in pain. Our results indicate that adults with long COVID are indeed significantly more likely to report both chronic and high-impact pain, but excluding individuals with COVID-19 from the analyses still showed substantial increases in pain prevalence. Thus, while the viral infections certainly had an impact, other societal and lifestyle changes that occurred during and after the pandemic may have contributed to the increase in pain. The role of increased social isolation and loneliness, disrupted health care access, and heightened levels of stress and anxiety, all of which were exacerbated by the pandemic, should be explored in future research.

This analysis marks the first comprehensive report on the escalation of chronic and high-impact pain after the pandemic in the US adult population. The findings are a call to action for public health professionals, policymakers, and researchers to further investigate the root causes of this increase. Addressing the rise in chronic pain is critical, as pain serves as a sensitive barometer of population health³¹ and has profound economic, social, and health consequences.

Our findings need to be replicated with other nationally-representative data sources such as the Health and Retirement Study, and a broader set of potential explanatory factors needs to be employed to explain the post-pandemic trends. Our findings indicated that chronic pain, already a widespread issue, has reached new heights in the post-pandemic era, necessitating urgent attention and intervention strategies to address and alleviate this growing health crisis.

REFERENCES

1. Gaskin DJ, Richard P. The economic costs of pain in the United States. *The journal of pain : official journal of the American Pain Society*. 2012;13(8):715-724. doi:10.1016/j.jpain.2012.03.009
2. Reynolds CA, Minic Z. Chronic Pain-Associated Cardiovascular Disease: The Role of Sympathetic Nerve Activity. *Int J Mol Sci*. Mar 11 2023;24(6)doi:10.3390/ijms24065378
3. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and Pain Comorbidity: A Literature Review. *Archives of Internal Medicine*. 2003;163(20):2433-2445. doi:10.1001/archinte.163.20.2433
4. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: A review of clinical and preclinical research. *Progress in Neurobiology*. 2011/03/01/ 2011;93(3):385-404. doi:<https://doi.org/10.1016/j.pneurobio.2011.01.002>
5. Piper A, Blanchflower DG, Bryson A. *Does pain lead to job loss? A panel study for Germany*. 2021. *National Bureau of Economic Research Working Paper Series*. <http://www.nber.org/papers/w28863>
6. Smith AA. Intimacy and family relationships of women with chronic pain. *Pain Management Nursing*. 2003;4(3):134-142. doi:10.1016/S1524-9042(03)00030-4
7. Flegge LG, Barr A, Craner JR. Sexual Functioning Among Adults with Chronic Pain: Prevalence and Association with Pain-Related Outcomes. *Pain Medicine*. 2023;24(2):197-206. doi:10.1093/pm/pnac117
8. Kelly GA, Blake C, Power CK, O'Keeffe D, Fullen BM. The Association Between Chronic Low Back Pain and Sleep: A Systematic Review. *The Clinical Journal of Pain*. 2011;27(2)
9. Office of Disease Prevention and Health Promotion [ODPHP]. Healthy People 2030. U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Accessed March 16, 2024, <https://health.gov/healthypeople>
10. Zimmer Z, Zajacova A. Persistent, Consistent and Extensive: The Trend of Increasing Pain Prevalence in Older Americans. *J Gerontol*. 2020;75(2):436-447. doi:10.1093/geronb/gbx162
11. Zajacova A, Grol-Prokopczyk H, Zimmer Z. Pain Trends Among American Adults, 2002–2018: Patterns, Disparities, and Correlates *Demography*. 2021;58(2):711–738. doi:10.1215/00703370-8977691
12. Wettstein M, Tesarz J. Increasing pain prevalence and intensity among middle-aged and older adults: Evidence from the German Ageing Survey. *Journal of Psychosomatic Research*. 2023/05/01/ 2023;168:111233. doi:<https://doi.org/10.1016/j.jpsychores.2023.111233>
13. Zimmer Z, Sun F, Duynisveld A. Are We Adding Pain-Free Years to Life? A Test of Compression Versus Expansion of Morbidity. *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences*. Aug 1 2024;79(8):glae157. doi:10.1093/gerona/glae157
14. Rikard SM, Strahan AE, Schmit KM, Guy GP, Jr. Chronic Pain Among Adults - United States, 2019-2021. *Morbidity and Mortality Weekly Report*. Apr 14 2023;72(15):379-385. doi:10.15585/mmwr.mm7215a1
15. Lamba S, Moffitt R. *The Rise in American Pain: The Importance of the Great Recession*. 2023. <https://ssrn.com/abstract=4512489>
16. Clauw DJ, Häuser W, Cohen SP, Fitzcharles M-A. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. *PAIN*. 2020;161(8):1694-1697. doi:10.1097/j.pain.0000000000001950
17. Shanthanna H, Nelson AM, Kissoon N, Narouze S. The COVID-19 pandemic and its consequences for chronic pain: a narrative review. *Anaesthesia*. 2022;77(9):1039-1050. doi:<https://doi.org/10.1111/anae.15801>

18. McFarland AJ, Yousuf MS, Shiers S, Price TJ. Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. *Pain Rep.* 2021;6(1):e885. doi:10.1097/pr9.0000000000000885
19. Wilson JM, Colebaugh CA, Flowers KM, Edwards RR, Schreiber KL. Profiles of Risk and Resilience in Chronic Pain: Loneliness, Social Support, Mindfulness, and Optimism Coming out of the First Pandemic Year. *Pain Medicine.* 2022;23(12):2010-2021. doi:10.1093/pm/pnac079
20. Meulders A, Vlaeyen JWS, Evers AWM, et al. Chronic primary pain in the COVID-19 pandemic: how uncertainty and stress impact on functioning and suffering. *PAIN.* 2022;163(4):604-609. doi:10.1097/j.pain.0000000000002428
21. Fernández-de-las-Peñas C, Navarro-Santana M, Plaza-Manzano G, Palacios-Ceña D, Arendt-Nielsen L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. *PAIN.* 2022;163(7):1220-1231. doi:10.1097/j.pain.0000000000002496
22. Romeiser JL, Morley CP, Singh SM. COVID-19 symptom load as a risk factor for chronic pain: A national cross-sectional study. *PLoS One.* 2023;18(6):e0287554. doi:10.1371/journal.pone.0287554
23. Khoja O, Silva Passadouro B, Mulvey M, et al. Clinical Characteristics and Mechanisms of Musculoskeletal Pain in Long COVID. *Journal of Pain Research.* 2022/06/17 2022;15(null):1729-1748. doi:10.2147/JPR.S365026
24. Williams LD, Zis P. COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine.* 2023;12(4):1672. doi:<https://doi.org/10.3390/jcm12041672>
25. Pitcher MH, Von Korff M, Bushnell MC, Porter L. Prevalence and Profile of High-Impact Chronic Pain in the United States. *The Journal of Pain.* 2019/02/01/ 2019;20(2):146-160. doi:<https://doi.org/10.1016/j.jpain.2018.07.006>
26. Blewett LA, Drew JAR, King ML, et al. e. Data from: IPUMS Health Surveys: National Health Interview Survey, Version 7.4 [dataset]. *IPUMS 2024.* 2024. *Minneapolis, MN.* doi:<https://doi.org/10.18128/D070.V7.4>
27. Duca LM, Helmick CG, Barbour KE, et al. A Review of Potential National Chronic Pain Surveillance Systems in the United States. *The Journal of Pain.* 2022;23(9):1492-1509. doi:10.1016/j.jpain.2022.02.013
28. IPUMS. *2019 NHIS Redesign.* n.d. Accessed September 15, 2022. https://nhis.ipums.org/nhis/userNotes_2019_NHIS_Redesign.shtml
29. Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. *Morbidity and Mortality Weekly Report.* 2018;67(36):1-6.
30. Yong RJ, Mullins PM, Bhattacharyya N. The prevalence of chronic pain among adults in the United States. *PAIN.* 2022;163(2): e328-e332. doi:10.1097/j.pain.0000000000002291
31. Zajacova A, Grol-Prokopczyk H, Zimmer Z. Sociology of Chronic Pain. *Journal of Health and Social Behavior.* 2021;62(3):302-317. doi:<https://doi.org/10.1177/00221465211025962>

TABLES AND FIGURES

Table 1. Prevalence of Pain in 2013, 2021, and 2023.


	2019		2021		2023		p-value
	N	Prevalence, (95% CI)	N	Prevalence, (95% CI)	N	Prevalence, (95% CI)	
Population size	250,334,186		252,461,316		257,760,200		
Global pain							
Chronic pain	50,154,951	20.6 (19.9-21.2)	51,490,798	20.9	60,713,114	24.3 (23.7-25.0)	<0.001
HICP	18,218,925	7.5 (7.1-7.8)	17,076,145	6.9	21,114,932	8.5 (8.1-8.9)	<0.001
Site-specific pain							
Back/neck	27,369,896	11.2	26,555,370	10.8	30,992,275	12.4	<0.001
Shoulder/arm	20,774,218	8.5	19,389,110	7.9	22,807,394	9.2	<0.001
Hip/knee/leg	29,652,413	12.2	28,200,773	11.5	32,575,447	13.1	<0.001
Head/migraine	11,623,361	4.8	10,478,580	4.3	13,832,320	5.6	<0.001
Abdominal	6,162,424	2.5	5,887,226	2.4	7,730,317	3.1	<0.001
Tooth/jaw	5,349,077	2.2	5,277,190	2.2	5,534,036	2.2	0.869

Weighted and adjusted for complex sampling design. P-values are from survey-adjusted Wald tests for difference across years.


Source: National Health Interview Survey, Adults 18 and older. HICP=high-income chronic pain.

Figure 1. Chronic pain in 2019, 2021, and 2023, US adults age 18+.

A. Chronic pain (CP)



B. High-impact chronic pain (HICP)



Note: prevalence estimates and 95% confidence intervals adjust for complex sampling design.

SUPPLEMENTAL MATERIAL

Supplemental Table S1. Sample characteristics in 2019, 2021, and 2023				
	Survey year			
	2019	2021	2023	Test
Population size	250,334,186	252,461,316	257,760,200	
Age (mean, s.d.)	47.7 (18.3)	48.1 (18.4)	48.1 (18.5)	0.081
Female	129,412,107 (51.7%)	130,389,168 (51.7%)	131,939,225 (51.2%)	0.539
Region of residence				0.954
Northeast	44,492,120 (17.8%)	44,060,428 (17.5%)	44,992,836 (17.5%)	
Midwest	52,661,442 (21.0%)	52,520,602 (20.8%)	53,077,517 (20.6%)	
South	94,302,024 (37.7%)	95,794,273 (37.9%)	98,869,532 (38.4%)	
West	58,878,600 (23.5%)	60,086,012 (23.8%)	60,820,315 (23.6%)	
Race/ethnicity				0.260
White	158,304,655 (63.2%)	158,598,869 (62.8%)	159,522,980 (61.9%)	
Black	29,378,731 (11.7%)	29,430,773 (11.7%)	30,364,132 (11.8%)	
Hispanic	41,439,638 (16.6%)	42,761,449 (16.9%)	45,261,461 (17.6%)	
Asian	14,703,362 (5.9%)	14,937,005 (5.9%)	16,187,251 (6.3%)	
Other	6,507,800 (2.6%)	6,733,220 (2.7%)	6,424,376 (2.5%)	
Foreign-born	45,162,051 (18.6%)	44,769,769 (18.3%)	46,729,314 (19.0%)	0.393
Marital status				0.004
Mar/cohab	149,086,612 (61.3%)	147,409,597 (60.4%)	148,533,425 (60.3%)	
Previously married	39,293,506 (16.2%)	38,461,741 (15.8%)	38,497,247 (15.6%)	
Never married	54,834,692 (22.5%)	58,306,151 (23.9%)	59,350,602 (24.1%)	
Education				<0.001
LHS/GED	36,791,321 (14.8%)	29,671,063 (11.8%)	32,861,727 (12.8%)	
HS	62,361,506 (25.1%)	65,324,595 (26.0%)	63,733,613 (24.9%)	
SC/AA	77,352,019 (31.1%)	66,749,842 (26.6%)	74,926,357 (29.2%)	
BA+	72,039,247 (29.0%)	89,168,590 (35.5%)	84,705,791 (33.1%)	
Food insecurity	20,798,082 (8.3%)	14,229,124 (5.6%)	22,119,891 (8.6%)	<0.001
Difficult to pay med. bills	34,235,025 (13.8%)	26,443,750 (10.5%)	27,361,167 (10.7%)	<0.001
Body mass index				<0.001
BMI < 18.5	4,012,552 (1.6%)	4,326,250 (1.7%)	4,059,011 (1.6%)	
18.5<=BMI<25	78,561,434 (31.4%)	77,314,310 (30.6%)	77,284,221 (30.0%)	
25<=BMI<30	82,616,122 (33.0%)	84,013,937 (33.3%)	85,755,233 (33.3%)	
BMI>=30	78,209,385 (31.2%)	81,015,576 (32.1%)	85,511,666 (33.2%)	
Unknown	6,934,693 (2.8%)	5,791,243 (2.3%)	5,150,069 (2.0%)	
Smoking status				<0.001
Current	34,015,663 (14.0%)	28,289,579 (11.6%)	26,952,716 (10.8%)	
Former	54,828,260 (22.5%)	56,266,805 (23.0%)	55,887,495 (22.5%)	
Never	154,376,037 (63.5%)	160,281,836 (65.5%)	165,699,129 (66.7%)	
Angina	4,209,203 (1.7%)	3,805,363 (1.5%)	4,112,172 (1.6%)	0.295
Arthritis	53,534,488 (21.4%)	53,685,652 (21.3%)	54,664,027 (21.2%)	0.886
Cancer	23,727,697 (9.5%)	24,655,468 (9.8%)	24,961,410 (9.7%)	0.550
CHD	11,513,251 (4.6%)	12,400,324 (4.9%)	12,403,444 (4.8%)	0.214
Diabetes	23,419,131 (9.4%)	24,254,223 (9.6%)	25,264,113 (9.8%)	0.253
Heart attack	7,863,199 (3.1%)	7,679,071 (3.0%)	7,780,823 (3.0%)	0.707
Hypertension	79,155,739 (31.7%)	79,386,312 (31.5%)	83,015,797 (32.3%)	0.220
High depression symptoms	23,577,423 (9.6%)	24,667,027 (10.0%)	26,367,464 (10.5%)	0.014
High anxiety symptoms	31,104,614 (12.7%)	31,754,918 (12.9%)	35,067,142 (14.0%)	<0.001
Health insurance				<0.001
Private	159,133,580 (63.8%)	162,229,570 (64.5%)	161,987,083 (63.2%)	
None	28,748,196 (11.5%)	24,751,534 (9.8%)	21,505,121 (8.4%)	
Public	61,350,733 (24.6%)	64,348,414 (25.6%)	72,953,116 (28.4%)	
COVID				
No covid			116,034,322 (45.0%)	.

Covid but not long	120,434,907 (46.7%)
Long but not now	12,130,433 (4.7%)
Long now but not hi	7,265,610 (2.8%)
HILC	1,894,928 (0.7%)

Weighted.

Supplemental Table S2. Prevalence ratios for CP and HICP in 2021 and 2023 relative to 2019 under different model specifications

	Chronic pain (CP)				High-impact chronic pain (HICP)			
	Model 1	Model 2	Model 3: no COVID	Model 4: no long COVID	Model 1	Model 2	Model 3: no COVID	Model 4: no long COVID
Year (2019)								
2021	1.01	1.07***	1.05**		0.92*	1.03	1.03	
2023	1.18***	1.22***	1.15***	1.19***	1.13***	1.19***	1.15***	1.16***
Covariates								
Age	1.02***	1.01***	1.01***	1.01***	1.03***	1.01***	1.01***	1.01***
Female	1.08***	0.99	0.99	0.97	1.25***	1.07*	1.07*	1.08*
Region (Northeast)								
Midwest		1.09**	1.09**	1.13***		1.07	1.09	1.10
South		1.08**	1.08**	1.08**		1.12*	1.13*	1.10
West		1.21***	1.22***	1.22***		1.28***	1.34***	1.25***
Race (White)								
Black		0.84***	0.85***	0.85***		0.91*	0.91*	0.87**
Hispanic		0.82***	0.80***	0.77***		0.92	0.88*	0.91
Asian American		0.65***	0.64***	0.67***		0.56***	0.57***	0.61***
Other		1.00	1.03	1.01		1.06	1.07	0.99
Foreign-born		0.82***	0.79***	0.81***		0.88*	0.87*	0.84**
Marital status (married)								
Previously married		0.99	1.00	0.99		1.01	1.02	0.99
Never married		0.83***	0.84***	0.83***		0.87**	0.88**	0.87*
Education (LHS)								
High school diploma		0.97	0.97	0.98		0.94	0.93	0.93
Some college or AA		1.03	1.05	1.02		0.96	0.98	0.96
BA+		0.88***	0.90***	0.88***		0.73***	0.74***	0.75***
Food insecure		1.21***	1.22***	1.23***		1.49***	1.53***	1.53***
Diff. paying medical bills		1.32***	1.31***	1.34***		1.52***	1.49***	1.51***
BMI (underweight)								
Normal weight		0.93	0.90	0.99		0.71***	0.70***	0.78*
Overweight		1.03	0.99	1.09		0.73***	0.70***	0.78*
Obese		1.21**	1.17*	1.28***		0.91	0.89	0.99
Smoking (current)								
Former		0.90***	0.88***	0.89***		0.88***	0.88**	0.87**
Never		0.74***	0.71***	0.75***		0.72***	0.71***	0.73***
Angina		1.05	1.07	1.05		1.13*	1.16*	1.09
Arthritis		2.49***	2.54***	2.43***		3.05***	3.07***	2.95***
Cancer		1.06***	1.06**	1.05*		1.08*	1.07	1.06
CHD		1.05*	1.05	1.09**		1.10*	1.09	1.14*
Diabetes		1.15***	1.15***	1.16***		1.25***	1.22***	1.25***
Heart attack		0.99	1.00	0.97		1.07	1.09	1.06
Hypertension		1.13***	1.14***	1.12***		1.27***	1.24***	1.22***
High depressive symptoms		1.42***	1.46***	1.43***		1.94***	1.99***	1.96***
High anxiety symptoms		1.49***	1.47***	1.50***		1.68***	1.66***	1.69***
Health insurance (private)								
No insurance		1.03	1.07	1.08		0.94	0.98	0.99
Public		1.14***	1.14***	1.17***		1.44***	1.47***	1.51***
N	87113	84871	67211	55156	87102	84865	67206	55153

Note: analyses take into account NHIS complex sampling design. Prevalence ratios from robust (modified) Poisson models. Models 3 and 4 includes only respondents who did not have COVID or long COVID, respectively. Model 4 only includes respondents in 2019 and 2023 because long COVID was not assessed in 2021.

Supplemental Table S3. Prevalence ratios for site-specific pain in 2021 and 2023 relative to 2019 under different model specifications												
	Back/neck pain		Arm/shoulder pain		Knee/hip/leg		Head/migraine		Abdominal/pelvic		Dental	
	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Year (2019)												
2021	0.95	1.03	0.91**	1.00	0.93**	1.00	0.89*	0.96	0.95	1.02	0.98	1.14
2023	1.10***	1.14***	1.06	1.13***	1.07*	1.12***	1.16***	1.17***	1.22***	1.24***	1.01	1.11
Covariates												
Age	1.01***	1.00***	1.02***	1.00**	1.02***	1.00***	0.99***	0.97***	1.00	0.98***	0.99***	0.98***
Female	1.28***	1.15***	1.29***	1.12***	1.34***	1.18***	2.65***	2.25***	2.17***	1.84***	1.32***	1.16**
Full set		✓		✓		✓		✓		✓		✓

The full set of covariates includes all those shown in Table S2.

Supplemental Table S4. Prevalence ratios for CP and HICP as a function of COVID, only 2023 data.

	COVID in the 2023 sample	Chronic pain (CP)		High-impact chronic pain (HICP)	
		Model 1	Model 2	Model 1	Model 2
COVID (didn't have)	44.7%				
Had COVID	46.9%	1.02	1.05*	0.90*	0.99
Had long COVID	4.7%	1.53***	1.31***	1.38***	1.11
Has long COVID now	2.9%	1.81***	1.30***	1.83***	1.13
Has high-impact long COVID	0.7%	2.67***	1.26**	4.83***	1.57***
Covariates					
Age		1.02***	1.01***	1.03***	1.01***
Female		1.03	0.96	1.22***	1.09
Full set			✓		✓

The full set of covariates includes all those shown in Table 1.

Note: analyses take into account NHIS complex sampling design. Prevalence ratios from robust (modified) Poisson models.

Only n=27,354 respondents from 2023 are included.